

EDITORIAL COMMENT

The Importance of Regurgitant Orifice Shape in Mitral Regurgitation*

Paul A. Grayburn, MD

Dallas, Texas

When you cannot measure it, . . . your knowledge is of a meagre and unsatisfactory kind; it may be the beginning of knowledge, but you have scarcely . . . advanced to the state of Science, whatever the matter may be.

—Kelvin (1)

In 1951, Gorlin and Gorlin (2) proposed the hydraulic orifice equation, based on the simple formula that orifice area equals flow divided by velocity.

$$A = F/V \quad [1]$$

Their idea was to calculate orifice area of stenotic heart valves from measurements of flow and velocity. Flow could be assessed by indicator-dilution methods, but velocity could not be measured because Doppler ultrasound had not yet been invented. Therefore, the Gorlins proposed to calcu-

[See page 1088](#)

late velocity from the pressure gradient, using the Torricelli law. For most of the 6 decades since their seminal paper, the Gorlin equation has been used to calculate the orifice area in mitral and aortic stenosis. Levine and Gaasch (3) showed that the Gorlin equation could be used to calculate regurgitant

volume (RgV) in regurgitant lesions such as mitral regurgitation (MR):

$$RgV = ROA \times C_d \times \sqrt{MPG} \times T \quad [2]$$

In Equation 2, ROA is regurgitant orifice area, C_d is a discharge coefficient accounting for energy loss, \sqrt{MPG} is the square root of the mean pressure gradient, and T is the time over which regurgitation occurs. Equations 1 and 2 can be rewritten as follows:

$$ROA = RgV/VTI \quad [3]$$

where RgV is regurgitant volume in milliliters and VTI is the velocity-time integral of the regurgitant jet in centimeters, as determined by Doppler ultrasound. VTI incorporates the mean gradient and the duration of regurgitant flow and is primarily determined by the systolic pressure difference between the left ventricle (LV) and left atrium (LA). VTI is independent of MR severity and generally falls within a fairly narrow range of values (except in acute MR, where the pressure gradient between the LV and LA is low). Thus, the 2 primary determinants of MR severity are ROA and RgV, which are linearly related. RgV can also be expressed as regurgitant fraction (RgF), which is the percentage of the total stroke output of the LV that is ejected retrograde into the LA. According to both the American Society of Echocardiography (4) and the American College of Cardiology/American Heart Association guidelines (5), ROA, RgV, and RgF are used together to determine MR severity.

In this issue of *iJACC*, Buchner et al. (6), report differences in the shape of the ROA in patients with MR of different etiologies. The investigators used cine cardiac magnetic resonance (CMR) to directly visualize the ROA in 74 patients with MR due to

*Editorials published in *JACC: Cardiovascular Imaging* reflect the views of the authors and do not necessarily represent the views of *JACC: Cardiovascular Imaging* or the American College of Cardiology.

From the Department of Internal Medicine, Division of Cardiology, Baylor University Medical Center, Baylor Heart and Vascular Institute, Dallas, Texas. Dr. Grayburn has received grant support from Abbott Vascular, Medtronic, Inc., Aastrom Biosciences, and Guided Delivery Systems. He has also received consulting fees from Abbott Vascular and Bracco Diagnostics.

varying causes. MR severity was classified as mild ($n = 29$), moderate ($n = 20$), or severe ($n = 25$) using RgF calculated by CMR. Etiology of MR was considered degenerative in 19 patients, leaflet prolapse in 15, flail leaflet in 25, and functional (secondary to LV dysfunction) in 15. The term “degenerative” was used unconventionally in this study to describe thickened, scarred leaflets, which are usually due to rheumatic heart disease, other post-inflammatory conditions, or anorectic drug use. The term “degenerative” is usually reserved for prolapse or flail leaflets due to myxomatous degeneration of leaflet and subvalvular tissues. Despite this faux pas, the investigators show convincingly that ROA is seldom circular in MR, but is elliptical or slitlike, particularly in functional MR. ROA shape index, defined as the long-axis divided by the short-axis of the elliptical ROA, was significantly larger for functional MR (3.9) than for mitral valve prolapse (2.1), flail (2.2), or “degenerative” etiology (1.2). Given that orifice shape is not a component of the hydraulic orifice equation, and therefore not a primary determinant of MR severity, is this finding clinically relevant?

To answer this question, one must consider that echocardiography has become the clinical standard for assessing MR severity. In clinical practice, MR severity is most often graded by “eyeballing” the size of regurgitant jet in the LA using color Doppler imaging. This is unfortunate because this method has been known to be inaccurate for 2 decades and is discouraged in the American Society of Echocardiography guidelines (4). In a recent report from our institution, almost one-half of patients referred for percutaneous treatment of severe MR with the MitraClip device (Abbott Vascular, Abbott Park, Illinois), did not have severe MR (7). The size of the color Doppler regurgitant jet within the LA is dependent on too many variables, including instrument settings, hemodynamics, jet eccentricity, and orifice geometry (4). With regard to the latter, slitlike orifices are analogous to placing one’s thumb over a water hose, creating a spray that may appear very large on color Doppler imaging. Moreover, when MR occurs through 2 separate orifices, color Doppler jets appear larger than would be expected for a single orifice of the same area (8). A good example of both situations is the bileaflet mechanical prosthetic valve, in which 3 separate regurgitant jets are seen in the LA during systole. Sometimes, these jets can appear fairly large, yet clinicians know that this is “trace” or “physiological” MR, and jet size is ignored.

Because of the known limitations of regurgitant jet area in evaluating MR severity, efforts have focused on imaging the ROA, either by vena contracta measurement, or by calculation from the size of the proximal isovelocity surface area (PISA) region (4). The vena contracta is the high velocity flow stream at or just downstream to the ROA. It conforms to ROA shape but is slightly smaller. Vena contracta width is a 1-dimensional measurement of the diameter of the ROA, which can be misleading if the ROA is not round. The vena contracta should be measured in a long-axis view, perpendicular to the largest diameter of the elliptical ROA (9). PISA calculation assumes a hemispheric shape to the proximal flow convergence region, which is only true for relatively round orifice shapes. Slitlike orifice shapes, such as those seen in functional MR, do not have a hemispheric PISA, which leads to underestimation of ROA (10,11). Even when vena contracta and PISA are carefully performed, significant interobserver variability exists in grading MR severity (12). Clearly, the best way to measure ROA is direct visualization by 3-dimensional (3D) imaging techniques. This has been done successfully with both 3D echocardiography (13–16) and with CMR (17).

Despite the ability to directly image the regurgitant orifice by CMR or 3D echocardiography, there are still challenges to overcome. Both methods use tomographic slices that are oriented 3 dimensionally. The actual ROA may curve out of the imaging plane. If there is more than 1 ROA, they may not be in the exact same imaging plane. Imaging artifacts such as Doppler blooming or CMR flow voids can be problematic. Temporal resolution must also be considered. In holosystolic MR, the ROA is dynamic and should ideally be measured as a mean value over systole. In mitral prolapse, MR may occur only in late systole, such that a single frame image of the ROA may significantly overestimate MR severity. Thus, it is important to consider both RgV and ROA to get a complete understanding of the severity of MR.

CMR provides a comprehensive evaluation of MR. ROA and RgV are the primary mathematical determinants of MR severity, and both can be measured quantitatively by CMR (18). In addition, LV volumes and ejection fraction are important in MR (5), and CMR is generally accepted as the most robust and reproducible clinical method for measuring them. Functional MR is a disease of the LV, in which structurally normal leaflets are restricted by ventricular enlargement, regional wall motion

abnormalities, and/or symmetrical or asymmetrical annular dilation. As shown in the Buchner et al. study (6), CMR offers the ability to measure leaflet tenting area, tethering distance, and the mitral annulus. Thus, CMR can evaluate the mechanism and severity of MR, as well as its impact on the LV.

Since the publication of the Sellers angiographic criteria (19), MR severity has been assessed qualitatively. Published guidelines (4,5) even recommend converting the quantitative measure of ROA, RgV, and RgF into descriptive categories such as mild, moderate, severe, or 1+ to 4+ on an ordinal scale. Even though such descriptive categories are

clinically meaningful (“mild” vs. “severe” MR), we now have imaging tools capable of accurate measurement of the quantitative, mathematical determinants of MR severity. To fully understand the complex pathophysiology of MR and evaluate new surgical or percutaneous therapies, it is important to be able to measure MR quantitatively.

Reprint requests and correspondence: Dr. Paul A. Grayburn, Baylor Heart and Vascular Institute, 621 North Hall Street, Suite H030, Dallas, Texas 75226. *E-mail:* paulgr@baylorhealth.edu.

REFERENCES

1. Kelvin. Available at: http://en.wikiquote.org/wiki/William_Thomson. Accessed August 15, 2011.
2. Gorlin R, Gorlin SG. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. *Am Heart J* 1951;41:1-29.
3. Levine HJ, Gaasch WH. Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. *J Am Coll Cardiol* 1996;28:1083-91.
4. Zoghbi W, Enriquez-Sarano M, Foster E, et al., for the American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. *J Am Soc Echocardiogr* 2003;16:777-802.
5. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease. *J Am Coll Cardiol* 2006;114:e84-231.
6. Buchner S, Poschenreider F, Hamer OW, et al. Direct visualization of regurgitant orifice by CMR reveals differential asymmetry according to etiology of mitral regurgitation. *J Am Coll Cardiol Img* 2011;4:1088-96.
7. Grayburn P, Roberts BJ, Aston S, et al. Mechanism and severity of mitral regurgitation by transesophageal echocardiography in patients referred for percutaneous valve repair. *Am J Cardiol* 2011; 108:882-7.
8. Lin BA, Forouhar AS, Pahlevan NM, et al. Color Doppler jet area overestimates regurgitant volume when multiple jets are present. *J Am Soc Echocardiogr* 2010;23:993-1000.
9. Roberts BJ, Grayburn PA. Color flow imaging of the vena contracta in mitral regurgitation: technical considerations. *J Am Soc Echocardiogr* 2003; 16:1002-6.
10. Yosefy C, Levine RA, Solis J, et al. Proximal flow convergence region as assessed by real-time 3-dimensional echocardiography: challenging the hemispheric assumption. *J Am Soc Echocardiogr* 2007;20:389-96.
11. Rifkin RD, Sharma S. An alternative isovelocity surface model for quantitation of effective regurgitant orifice area in mitral regurgitation with an elongated orifice application to functional mitral regurgitation. *J Am Coll Cardiol Img* 2010;3:1091-103.
12. Biner S, Rafique A, Raffi F, et al. Reproducibility of proximal isovelocity surface area, vena contracta, and regurgitant jet area for assessment of mitral regurgitation severity. *J Am Coll Cardiol Img* 2010;3:235-43.
13. Kahlert P, Plicht B, Schenk IM, Janosi A, Erbel R, Buck T. Direct assessment of size and shape of non-circular vena contracta area in functional versus organic mitral regurgitation using real-time three-dimensional echocardiography. *J Am Soc Echocardiogr* 2008;21: 912-21.
14. Little SH, Pirat B, Kumar R, et al. Three-dimensional color Doppler echocardiography for direct measurement of vena contracta area in mitral regurgitation: in vitro validation and clinical experience. *J Am Coll Cardiol Img* 2008; 1:695-704.
15. Yosefy C, Hung J, Chua S, et al. Direct measurement of vena contracta area by real-time 3-dimensional echocardiography for assessing severity of mitral regurgitation. *Am J Cardiol* 2009;104:978-83.
16. Zeng X, Levine RA, Hua L, et al. Diagnostic value of vena contracta area in the quantitation of mitral regurgitation severity by color Doppler 3D echocardiography. *Circ Cardiovasc Imaging* 2011 Jul 5 [E-pub ahead of print].
17. Buchner S, Debi K, Poschenreider F, et al. Cardiovascular magnetic resonance for direct assessment of anatomic regurgitant orifice in mitral regurgitation. *Circ Cardiovasc Imaging* 2008;1:148-55.
18. Hundley WG, Li HF, Willard JE, et al. Magnetic resonance imaging assessment of the severity of mitral regurgitation: comparison with invasive techniques. *Circulation* 1995;92:1151-8.
19. Sellers RD, Levy MJ, Amplatz K, Lillehei CW. Left retrograde cardioangiography in acquired cardiac disease: technic, indications, and interpretation in 700 cases. *Am J Cardiol* 1964;14:437-47.

Key Words: cardiac magnetic resonance ■ mitral valve ■ regurgitant orifice ■ regurgitation.